Sentinel Node Biopsy Versus Limited Elective Neck Dissection in Early Cancers of Oral Cavity NoDe Negative
Launched by TATA MEMORIAL HOSPITAL · Mar 7, 2023
Trial Information
Current as of June 18, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is comparing two different surgical approaches for treating early-stage mouth cancers that have not spread to the lymph nodes. The trial focuses on understanding which method leads to better survival rates, fewer complications, and is more cost-effective. Participants will be assigned to one of two groups: one group will have a sentinel node biopsy, where doctors check a specific lymph node for cancer and may perform additional surgery if needed. The other group will have a limited neck dissection, where only certain lymph nodes are removed based on whether they show signs of cancer.
To be eligible for this trial, participants must be over 18 years old, have a confirmed diagnosis of early-stage squamous cell carcinoma in the mouth (specifically in the tongue or cheek areas), and show no signs of cancer in the lymph nodes during exams. Patients who have had previous head and neck surgeries or have other specific types of lesions will not be included. Throughout the trial, participants can expect close monitoring and follow-up to understand the outcomes of each surgical approach. This study is currently recruiting participants, and it aims to provide valuable insights that could improve treatment for patients with early oral cancers.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age \>18 years of age
- • 2. Biopsy-proven invasive squamous cell carcinoma involving the site tongue and buccal mucosa
- • 3. T1 and T2 lesions as per AJCC TNM 8 edition
- • 4. Clinicoradiologically node negative
- • 5. Amenable to per oral excision
- • 6. Treatment naïve
- • 7. No other site of malignancy
- Exclusion Criteria:
- • 1. Previous surgery in the head and neck region,
- • 2. Upper alveolar or palatal lesions
- • 3. Large heterogeneous leukoplakia or other premalignant lesions
- • 4. Previous malignancy in the head and neck region
- • 5. Patients requiring the free flap reconstruction
About Tata Memorial Hospital
Tata Memorial Hospital (TMH) is a premier cancer treatment and research institution located in Mumbai, India, dedicated to providing comprehensive cancer care, conducting advanced research, and offering education in oncology. Established in 1941, TMH is recognized for its commitment to improving cancer treatment outcomes through innovative clinical trials and translational research. The hospital plays a pivotal role in the development of new therapies and treatment protocols, collaborating with national and international research organizations to enhance the understanding of cancer biology and improve patient care. With a multidisciplinary team of experts, TMH strives to foster a compassionate environment that prioritizes patient welfare while advancing scientific knowledge in the field of oncology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mumbai, Maharashtra, India
Mumbai, Maharashtra, India
Navi Mumbai, Maharashtra, India
Varanasi, Uttar Pradesh, India
Patients applied
Trial Officials
Richa Vaish, MS, M.Ch
Principal Investigator
Tata Memorial Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials